As a hematologist-oncologist with global biopharma experience, Alf knows how to resolve complex challenges to deliver improved outcomes. His positive outlook and strategic thinking inspire clients to embrace innovative approaches to deliver therapies to patients. 

Alf joined The NemetzGroup in 2025 with over 15 years in biopharma industry roles and 10 years as a physician consultant in oncology, hematology, and palliative care in academia. His leadership experience in medical affairs spans global, regional, and local levels. Alf brings a remarkable combination of clinical expertise, strategic leadership, and global perspective that further strengthens our ability to support clients navigating the complex landscape of commercializing their assets, especially those in hematology, oncology, and cell therapy. 

Most recently, Alf served as Head of Pipeline and Cell Therapy, Global Medical Affairs Oncology at Takeda in Cambridge, where he led cross-functional global teams driving early pipeline strategy, scientific communications, and external engagement. Prior to that, he established and led European Medical Affairs at Seattle Genetics (now Seagen), building the team and infrastructure needed to support key oncology launches across the region. Earlier in his career at Roche/Genentech, Alf directed global medical strategies for the HER2+ breast cancer portfolio, earning the company’s Excellence Award for Courage in 2017. He is known for his strategic insight, collaborative approach, and focus on innovation that advances patient care and elevates medical affairs teams.  

Alf remains active in the professional oncology community through his membership in DGHO, ASCO, and ASH. After earning a PhD thesis at the Institute of Medical Microbiology and Virology, University Clinic, Alf received his MD from the University Hospital of Hematology, Oncology, and Clinical Immunology in Duesseldorf, Germany.